Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00309478
Status:
COMPLETED
Last Update Posted:
2023-06-29
First Post:
2006-03-31
Brief Title:
Randomized Study Comparing CMF and Goserelin Tamoxifen in Premenopausal Receptor-positive Patients
Sponsor:
Austrian Breast Colorectal Cancer Study Group
Organization:
Austrian Breast Colorectal Cancer Study Group
Study Overview
Official Title:
A Randomized Phase III Study Comparing Cyclophosphamide Methotrexate Fluorouracil vs Goserelin Tamoxifen in Premenopausal Hormone Receptor-positive Lymph Node-positive or -Negative Patients
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primarily this clinical investigation compared the efficacy of cyclophosphamide methotrexate fluorouracil chemotherapy vs goserelin tamoxifen treatment in terms of prognosis disease-free survival overall survival in premenopausal patients with potentially curative operated hormone receptor-positive breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None